9 October 2015: Tapclob (clobazam) advert
Published 25 November 2015
© Crown copyright 2015
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-october-2015/9-october-2015-tapclob-clobazam-advert
Perrigo complained about a journal advert for Tapclob produced by Martindale Pharma for healthcare professionals which was published in July 2015. The complainant was concerned that the statement “MHRA guidance advises that switching between different branded or generic products of the same antiepileptic drug could harm your patients” in the advert was inconsistent with the referenced Commission on Human Medicines (CHM) advice and was therefore misleading.
MHRA did not uphold the complaint but advised Martindale that for future advertising, to ensure it was clear that the potential for harm arose from unplanned or unsupervised switching between products.